Brain Neoplasms, Malignant
6
1
1
1
Key Insights
Highlights
Success Rate
25% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
50.0%
3 terminated out of 6 trials
25.0%
-61.5% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Risk Factors for Adult-Onset Brain Tumors
CEST- Glucose Enhanced MRI for Metastatic Brain Tumours
Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors